Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.

Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.

Best Pract Res Clin Haematol. 2001 Jun;14(2):401-36. Review.

PMID:
11686107
2.

Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Semin Thromb Hemost. 2006 Sep;32(6):577-88. Review.

PMID:
16977568
3.

Acquired von Willebrand syndrome: features and management.

Mohri H.

Am J Hematol. 2006 Aug;81(8):616-23. Review.

4.

Acquired von Willebrand syndrome--report of 10 cases and review of the literature.

Nitu-Whalley IC, Lee CA.

Haemophilia. 1999 Sep;5(5):318-26. Review.

PMID:
10583513
5.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
6.

Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.

Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Semin Thromb Hemost. 2005 Nov;31(5):577-601. Review.

PMID:
16276467
7.

Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.

Michiels JJ, Schroyens W, Berneman Z, van der Planken M.

Clin Appl Thromb Hemost. 2001 Apr;7(2):113-5. Review.

PMID:
11292187
8.

Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.

Federici AB.

Hum Immunol. 2005 Apr;66(4):422-30. Review.

PMID:
15866707
10.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
11.

Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. Review.

PMID:
16959681
12.

Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Mohri H.

J Thromb Thrombolysis. 2003 Jun;15(3):141-9. Review.

PMID:
14739623
13.

Acquired von Willebrand's syndrome: a single institution experience.

Kumar S, Pruthi RK, Nichols WL.

Am J Hematol. 2003 Apr;72(4):243-7. Review.

14.
15.

Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.

Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.

Acta Haematol. 2009;121(2-3):145-53. doi: 10.1159/000214855. Epub 2009 Jun 8. Review.

PMID:
19506361
16.

Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Clin Appl Thromb Hemost. 2006 Oct;12(4):397-420. Review.

PMID:
17000885
17.

Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.

Sucker C, Michiels JJ, Zotz RB.

Acta Haematol. 2009;121(2-3):177-82. doi: 10.1159/000214858. Epub 2009 Jun 8. Review.

PMID:
19506364
18.

Diagnosis and management of acquired von Willebrand syndrome.

Federici AB, Mannucci PM.

Clin Adv Hematol Oncol. 2003 Mar;1(3):169-75. Review.

PMID:
16224398
19.

Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.

Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.

Semin Thromb Hemost. 2006 Sep;32(6):636-45. Review.

PMID:
16977574
20.

Acquired von Willebrand disease in myeloproliferative disorders.

van Genderen PJ, Leenknegt H, Michiels JJ, Budde U.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:79-82. Review.

PMID:
8951776

Supplemental Content

Support Center